U.S. Department of Health and Human Services
Griffin Rodgers

 Contact Info

Tel: 301-496-5741
Email: griffin.rodgers@nih.gov

 Select Experience

  • M.B.A.Johns Hopkins University2005
  • M.D.Brown University1979
  • M.M.Sc.Brown University1979
  • Sc.B.Brown University1976

 Related Links


 Director's Biography

View Dr. Rodgers' Director's Biography.​

Griffin P. Rodgers, M.D., M.A.C.P.

Director, Office of the Director​
Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology Section, Molecular and Clinical Hematology Branch

Specialties: Molecular Biology/Biochemistry, Chemistry/Chemical Biology, Genetics/Genomics, Hematology​​​

Griffin P. Rodgers, M.D., M.A.C.P

Chief, Molecular and Clinical Hematology Branch
Section Chief, Molecular Hematology SectionMolecular and Clinical Hematology Branch
Director, Office of the Director
  • Chemistry/Chemical Biology
  • Genetics/Genomics
  • Hematology
  • Molecular Biology/Biochemistry
Research Summary/In Plain Language

Research in Plain Language

Dr. Rodgers conducts research on human blood diseases. He also develops and validates experimental models that researchers can use to describe regulatory mechanisms in the normal and abnormal formation of blood cells. This area of research contributes to the development of medications or genetic approaches to correct or compensate for abnormalities caused by diseases. Another important aspect of his work focuses on finding ways to speed the translation of new research findings to preclinical or clinical study.

He plans and conducts research on the molecular and cellular bases of inherited and acquired blood disorders, develops quantitative methods to describe how a disease is acting and how severe it is, and studies the ways and differences in how genes are expressed in developing and mature red blood cells.

He also studies the molecular basis of differences in ways that normal and diseased blood cells develop in bone marrow and the lymphatic system, and develops therapies for genetic blood disorders. Dr. Rodgers contributed to the development of the first effective—and now FDA approved—therapy for sickle cell anemia: the drug hydroxyurea. Recent research has shown that people with sickle cell anemia who took hydroxyurea at the recommended dose had higher survival rates than those who took less than the recommended dose.

Another treatment approach, a new blood stem-cell transplant regimen, effectively reversed sickle cell disease in 26 of 30 adult participants and allowed them to achieve stable mixed donor chimerism, a condition in which a person has two genetically distinct cell types in the blood. Also of importance, more than half of adults were able to stop taking immunosuppressant medications 1 year after transplantation. This study represents an important advance to make a potentially transformative treatment available to a wider range of people, especially those who could not tolerate a standard stem cell transplant or long-term use of immunosuppressant medications.  These results were recently replicated in 12 adult patients at the University of Illinois.